Evaxion Biotech AS Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
| EVAX Stock | USD 1.54 0.12 7.23% |
Slightly above 61% of Evaxion Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Evaxion Biotech AS suggests that many traders are alarmed. Evaxion Biotech's investing sentiment can be driven by a variety of factors including economic data, Evaxion Biotech's earnings reports, geopolitical events, and overall market trends.
Evaxion |
Evaxion Biotech AS Reports Earnings Results for the Full Year Ended December 31, 2023 Marketscreener.com
Read at news.google.com
 |
Evaxion Biotech Fundamental Analysis
We analyze Evaxion Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evaxion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evaxion Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Evaxion Biotech is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Evaxion Biotech AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evaxion Biotech stock to make a market-neutral strategy. Peer analysis of Evaxion Biotech could also be used in its relative valuation, which is a method of valuing Evaxion Biotech by comparing valuation metrics with similar companies.
Peers
Evaxion Biotech Related Equities
| REVB | Revelation Biosciences | 25.00 | ||||
| PHIO | Phio Pharmaceuticals | 7.35 | ||||
| UNCY | Unicycive Therapeutics | 7.25 | ||||
| QNRX | Quoin Pharmaceuticals | 6.67 | ||||
| LYEL | Lyell Immunopharma | 5.26 | ||||
| BDRX | Biodexa Pharmaceticals | 4.09 | ||||
| VRAX | Virax Biolabs | 1.02 | ||||
| GLUE | Monte Rosa | 1.35 | ||||
| ALLR | Allarity Therapeutics | 1.82 | ||||
| CGEM | Cullinan Oncology | 2.08 | ||||
| RVPH | Reviva Pharmaceuticals | 3.23 | ||||
| ZVSA | ZyVersa Therapeutics | 3.74 | ||||
| ZURA | Zura Bio | 8.20 | ||||
| RVMD | Revolution Medicines | 10.46 | ||||
| RNAZ | Transcode Therapeutics | 20.00 |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.